Article

Study targets therapies for endophthalmitis

Study evaluates novel and traditional antifungal agents to determine efficacy.

By Kenneth C. Fan, MD, MBA

Ophthalmology Times is pleased to recognize Kenneth C. Fan, MD, MBA, resident, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, as the fourth-place honoree of the second Ophthalmology Times Research Scholar Honoree Program. Dr. Fan’s abstract is featured here. The Ophthalmology Times Research Scholar Honoree Program is dedicated to the education of retina fellows and residents by providing a unique opportunity for fellows/residents to share notable research and challenging cases with their peers and mentors. The program is supported by unrestricted grants from Regeneron Pharmaceuticals and Carl Zeiss Meditec Inc.

PURPOSE

Fungal endophthalmitis can be associated with long treatment courses and poor outcomes. Newer antifungal agents are currently available but limited data is published on their effectiveness Some newer, more expensive therapies have not been compared to more traditional drugs.

METHODS

In our study, we conducted a retrospective review of app patients with positive vitreous cultures of candida species from Jan. 1, 2011, to Sept. 30, 2017. Frozen samples were inoculated with 10,000 CFU/mL of yeast broth at a temperature of 350 C for 48 hours. Antifungal sensitivities to Candida were obtained for the following:

  • Echinocandins (Caspofungin, Anidulafungin, Micafungin)

  • Triazoles (Voriconazole, Posaconazole, Itraconazole, Fluconazole)

  • Polyenes (Amphotericin B)

  • Nucleoside Analogs (5-Flucytosine)

RESULTS

Using ETEST strips and microdilution plats, a total of 17 Candida isolates were identified:

  • C. albicans (10)

  • C. glabrata (3)

  • C. parapsilosis (2)

  • C. tropicalis (2)

We also reviewed drug efficacy. We found that Amphotericin B is efficacious but can be toxic to retinal ganglion cells at even levels as low as 5μg (Tremblay et al.).

Voriconazole MIC90 was lower than other triazoles, and Anidulafungin MIC90 higher than other echinocandins. Voriconazole also has shown lower ocular toxicity, better penetration, and good clinical outcomes.

There is a growing body of case reports demonstrating clinical efficacy. In a comparison with other drug classes, there were two successful case reports of intravitreal caspofungin, and safety studies demonstrated no evidence of toxicity on ERG vs. NaCl.

In one rabbit model case series of 24 eyes vs. Voriconazole and Amphotericin B, it was clinically more effective (p < 0.05), and the retinal toxicity was lower than other groups (p < 0.05).

CONCLUSIONS

We found that both newer and traditional antifungal agents are generally effective. Mild candida resistance was seen with fluconazole (older) and anidulafungin (newer). Newer therapies are not necessarily more efficacious than traditional drugs. In-classagents, Voriconazole showed<MIC than fluconazole, itraconazole, posaconazole.  Micafungin showed <MIC than caspofungin, anidulafungin.

We have found that further studies investigating these newer antifungals are necessary.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.